sEH studies have resulted in over 800 publications in top-tier peer-reviewed journals.

sEH Pathway  

The technology at AccenGen is focused on developing inhibitors of the soluble epoxide hydrolase (sEH) and dual COX/sEH inhibitors. sEH is a novel target for inflammation, allowing an opportunity to target multiple indications with inflammatory components. sEH plays an important role in the metabolism of lipid epoxides, which are endogenous molecules known as epoxyeicosatrienoic acids (EETs). EETs are effective regulators of inflammation. Hydrolysis by sEH converts EETs to the corresponding diols with diminished anti-inflammatory effects. Inhibition of sEH leads to accumulation of active EETs and thus provides a novel approach to the treatment of inflammation. sEH pathway is a true anti-inflammatory pathway, unlike most medications which target inflammatory pathways, such as the cyclooxyrgenase (COX) and lipooxygenase (LOX) inhibitors. This enables the ability to target inflammation at its source and minimize adverse side-effects.